Form 4: Castle Biosciences CEO Derek Maetzold Sells Shares Under 10b5-1 Plan

Derek Maetzold, CEO of Castle Biosciences, executed multiple sales of common stock on November 4, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On November 4, 2024, Derek J Maetzold, the President and CEO of Castle Biosciences, sold shares of the company's common stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 24, 2024.
• The transactions involved multiple sales at prices ranging from $32.130 to $33.155 per share.
• Maetzold sold shares directly and indirectly through various trusts for which he serves as trustee or has beneficial interest.
• The trusts involved include The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, and several Maetzold 2018 Remainder Trusts for the benefit of his children.
• Following the reported transactions, Maetzold continues to hold a significant number of shares directly and indirectly through these trusts.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting insider trading activity. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This is a routine disclosure of insider trading activity. It's common for executives to have pre-arranged trading plans to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates